Farxiga (Dapagliflozin) in Geriatric Patients (65+): Transition to Adult Care

What Dapagliflozin Does and Why Age Matters

Dapagliflozin blocks sodium-glucose cotransporter-2 (SGLT2) in the proximal tubule, reducing glucose reabsorption and producing glycosuria, mild natriuresis, and a modest osmotic diuresis. In younger adults these effects are generally well tolerated. In adults aged 65 and older, the same mechanism operates on a background of reduced glomerular filtration, lower total body water, blunted thirst sensation, and a higher baseline medication burden. Those physiological differences shift both the benefit-risk calculation and the monitoring schedule.

The FDA label for Farxiga does not specify a geriatric dose adjustment, but it does specify eGFR thresholds that effectively govern older patients more often than younger ones. The 2023 FDA-approved Farxiga prescribing information states that no dose adjustment is needed based on age alone, while also noting that elderly patients may be more susceptible to volume depletion-related adverse reactions.

The Three Approved Indications in Older Adults

Type 2 Diabetes (T2D)

The glycemic indication requires eGFR of at least 45 mL/min/1.73m². Because roughly 38% of U.S. Adults over age 65 have an eGFR below 60 mL/min/1.73m² according to CDC chronic kidney disease surveillance data, a meaningful proportion of geriatric patients with T2D will reach the threshold where the glycemic indication must be stopped while cardiorenal indications may continue.

Heart Failure

The DAPA-HF trial (N=4,744) tested dapagliflozin 10 mg versus placebo in patients with heart failure and reduced ejection fraction (HFrEF). The primary composite of worsening heart failure or cardiovascular death was reduced by 26% (hazard ratio 0.74, 95% CI 0.65 to 0.85, P<0.001). McMurray et al., NEJM 2019 reported that the benefit was consistent across patients aged 65 and older, who comprised approximately 55% of the enrolled population.

Chronic Kidney Disease

In DAPA-CKD (N=4,304), dapagliflozin reduced the composite of sustained 50% eGFR decline, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) compared with placebo. Heerspink et al., NEJM 2020 confirmed that patients with eGFR as low as 25 mL/min/1.73m² benefited, which is especially relevant for older adults who are often excluded from glycemic dosing but retain a CKD or HF indication.

How Aging Physiology Changes the Risk Profile

Older adults are not simply older versions of younger adults. Four physiological changes materially alter how dapagliflozin behaves in a 72-year-old compared to a 42-year-old.

Reduced Glomerular Filtration Rate

Age-related nephron loss lowers average eGFR by roughly 1 mL/min/1.73m² per year after age 40. A patient who tolerated dapagliflozin at age 62 with an eGFR of 58 may cross the eGFR <45 threshold by age 68, removing the glycemic benefit while the cardiorenal benefit persists. Clinicians managing this transition should reassess the primary indication at every annual visit and pivot the documentation when eGFR milestones are crossed.

Volume Depletion and Orthostatic Hypotension

Dapagliflozin's osmotic diuresis, though modest compared with loop diuretics, may compound pre-existing volume contraction in older patients. A 2019 cohort analysis published in JAMA Internal Medicine found that SGLT2 inhibitor initiation was associated with a lower risk of serious adverse renal events compared with DPP-4 inhibitors, but the same analysis identified a higher absolute event rate for acute kidney injury in patients already on loop diuretics or ACE inhibitors. Geriatric patients who are diuretic-dependent deserve a baseline orthostatic blood pressure check before dapagliflozin is started.

Bone Mineral Density and Fracture Risk

Early pooled analyses raised concern about fractures with SGLT2 inhibitors, partly related to canagliflozin data. Dapagliflozin-specific data from DECLARE-TIMI 58 (N=17,160, median age 64 years) found no statistically significant increase in fracture risk compared with placebo. Wiviott et al., NEJM 2019 reported fracture rates of 4.3% in the dapagliflozin arm versus 4.4% in placebo. For a geriatric patient with pre-existing osteoporosis, this reassurance is meaningful, though fall risk from volume depletion remains a separate concern.

Polypharmacy and Drug Interactions

Adults over 65 take an average of 5.8 prescription medications according to CDC National Health and Nutrition Examination Survey data. Dapagliflozin's most clinically significant interactions in this context involve:

• Loop diuretics (additive volume depletion)
• ACE inhibitors and ARBs (compounded hyperkalemia risk in CKD stages 3b to 4)
• Insulin and sulfonylureas (hypoglycemia risk; reduce insulin dose by 15 to 20% at initiation per prescribing information)
• NSAIDs (acute tubular toxicity in a patient already experiencing osmotic diuresis)

eGFR Thresholds: A Practical Transition Framework

The most common clinical challenge when managing dapagliflozin across the lifespan is deciding what to do when eGFR crosses a threshold. The following framework clarifies each decision point specifically for geriatric patients.

eGFR 60 or Above

No restriction applies. Continue 10 mg daily for any approved indication. Monitor eGFR annually unless the patient has CKD stage 3a or above, in which case monitor every 6 months per KDIGO 2022 CKD guidelines.

eGFR 45 to 59

The glycemic indication is technically permitted but glycemic efficacy declines as eGFR falls. The 2023 American Diabetes Association Standards of Care (section 9, pharmacologic approaches) note that at eGFR 45 to 59, SGLT2 inhibitors provide reduced glucose-lowering but retain cardiorenal benefit. ADA Standards of Care 2023 recommend continuing the drug if a cardiorenal indication exists, even when glycemic benefit is marginal.

eGFR 25 to 44

Stop dapagliflozin for glycemic purposes. Continue at 10 mg daily if the patient carries an HF or CKD diagnosis. Reassess hydration status at each visit. Consider reducing loop diuretic dose by 25 to 50% if the patient reports lightheadedness or shows a 3 to 5 lb weight drop within the first two weeks.

eGFR Below 25

Discontinue for all indications. The FDA prescribing information and the DAPA-CKD trial did not enroll patients with eGFR below 25 for the CKD indication (the lower enrollment bound was eGFR 25 mL/min/1.73m²), so efficacy data below this threshold are absent. Dialysis-dependent patients are explicitly excluded from use.

Transitioning from Younger-Adult to Geriatric Protocols

When a patient who started dapagliflozin at age 50 to 60 crosses into the geriatric age category, several protocol elements should be reassessed.

What to Reassess at Age 65

Clinicians should document the current eGFR and compare it with the baseline at drug initiation. A fall of more than 15 mL/min/1.73m² since initiation suggests progressive CKD requiring nephrology co-management. The prescribing information notes that acute decreases in eGFR of 10 to 15% are common within the first two to four weeks and are generally reversible. A 2021 post-hoc analysis of DAPA-CKD in JASN confirmed that an early eGFR dip at week 2 to 4 predicted better long-term renal preservation, not harm, in patients with CKD.

Adjusting Concomitant Diabetes Medications

Geriatric patients frequently arrive at age 65 on combinations of metformin, insulin, a sulfonylurea, and dapagliflozin. Metformin should be dose-reduced at eGFR <45 and stopped at eGFR <30. Sulfonylureas carry a higher hypoglycemia risk in older adults with reduced caloric intake, delayed gastric emptying, and unpredictable oral intake. The combination of a sulfonylurea with dapagliflozin at eGFR 45 to 59 should prompt a documented hypoglycemia-risk conversation and possible sulfonylurea dose reduction, particularly for glibenclamide (glyburide), which is best avoided in adults over 65 per the Beers Criteria. The 2023 AGS Beers Criteria classifies glyburide as potentially inappropriate in older adults because its active metabolites accumulate with reduced renal clearance.

Blood Pressure and Cardiovascular Monitoring

Dapagliflozin lowers systolic blood pressure by roughly 2 to 4 mmHg. In a geriatric patient already on a calcium channel blocker and a thiazide, this modest reduction may push standing systolic pressure below 100 mmHg. Orthostatic hypotension affects approximately 20% of community-dwelling adults over 65 according to Ricci et al., BMJ 2015. A standing blood pressure measurement 1 minute after rising should be documented at each outpatient visit for the first 6 months after dapagliflozin initiation in this age group.

Genital Mycotic and Urinary Tract Infections in Older Adults

Glycosuria creates a substrate-rich environment for Candida albicans. In DECLARE-TIMI 58, genital mycotic infections occurred in 4.3% of women and 2.4% of men on dapagliflozin versus 1.3% and 0.7% in placebo. Wiviott et al., NEJM 2019 reported that the vast majority of these infections were mild to moderate and responded to standard antifungal therapy.

In postmenopausal women, vaginal atrophy reduces local immune defenses, making genital mycotic infections both more frequent and more symptomatic. Clinicians should ask specifically about vulvovaginal symptoms at each visit. First-line treatment is a single-dose oral fluconazole 150 mg; recurrent infections (three or more per year) warrant a 6-month suppressive regimen per standard infectious disease guidelines.

Urinary tract infections were not significantly increased with dapagliflozin in DECLARE-TIMI 58, which contrasts with earlier canagliflozin data. Still, geriatric women with recurrent UTIs, urinary incontinence, or indwelling catheters may be at higher baseline risk, and this conversation should happen before prescribing.

Euglycemic Diabetic Ketoacidosis: A Rare but Serious Risk

Euglycemic DKA (euDKA) is more common in elderly patients undergoing surgical procedures or prolonged fasting. Blood glucose may be below 250 mg/dL, making the diagnosis easy to miss. The FDA issued a safety communication in 2015 requiring SGLT2 inhibitor labels to carry a warning for DKA.

For geriatric patients:

• Hold dapagliflozin at least 3 days before any elective surgery, procedure requiring general anesthesia, or prolonged NPO period.
• Restart only after full oral intake has resumed and ketone levels are normal.
• Patients on low-carbohydrate diets are at higher ketosis risk even without a surgical trigger.

The NICE guideline NG28 (Type 1 Diabetes in Adults, updated 2022) and the ABCD/JBDS sick-day rules guidance both recommend the "SADMAN" rule (Stop SGLT2 inhibitors during Sickness, Accident, Dehydration, Missed meals, Any surgery, and starvation / NPO status).

Cardiovascular Outcomes in Older Adults: What the Trials Show

DECLARE-TIMI 58 Age Subgroup

DECLARE-TIMI 58 enrolled 17,160 patients with T2D and either established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors. Median age was 64 years. The primary safety outcome (MACE: cardiovascular death, MI, or stroke) was not significantly reduced overall (HR 0.93, 95% CI 0.84 to 1.03), but the HHF (hospitalization for heart failure) plus cardiovascular death composite was reduced by 17% (HR 0.83, 95% CI 0.73 to 0.95). Wiviott et al., NEJM 2019 showed consistent benefit across the 65 and older subgroup for the HHF endpoint.

DAPA-HF in Patients Over 65

In a pre-specified subgroup analysis of DAPA-HF, patients over 65 showed a hazard ratio for the primary composite of 0.72 (95% CI 0.60 to 0.86), slightly better than the overall trial result of 0.74. This suggests older patients with HFrEF derive at least as much benefit as younger counterparts, a finding that should directly inform prescribing decisions in geriatric cardiology clinics. McMurray et al., NEJM 2019.

Monitoring Schedule for Geriatric Patients on Dapagliflozin

A systematic monitoring plan reduces the risk of missing the clinical signals that are most common in older patients.

Baseline Before Starting

• Serum creatinine and eGFR
• Urinalysis (to rule out active UTI before initiating glycosuria)
• Orthostatic blood pressure (supine and 1 minute standing)
• Current medication list reviewed for loop diuretics, NSAIDs, sulfonylureas, and insulin
• Urine albumin-to-creatinine ratio (UACR) if CKD indication is being used

At 2 to 4 Weeks

• Repeat eGFR (an early dip of up to 15% is expected and does not require discontinuation)
• Weight and blood pressure (flag any drop exceeding 4 to 5 lbs from baseline as possible excess volume depletion)
• Symptom review: lightheadedness, urinary urgency, genital itching

At 3 Months and Annually

• eGFR, UACR, serum potassium
• HbA1c if T2D indication is active
• Falls assessment using the CDC STEADI algorithm

The 2022 ADA Standards of Care recommend checking eGFR at least twice per year in CKD stage 3b to 4 patients on SGLT2 inhibitors.

Special Populations Within the Geriatric Group

Frail Older Adults

Frailty is defined by the Fried criteria as three or more of: unintentional weight loss, exhaustion, low grip strength, slow walking speed, and low physical activity. Fried et al., J Gerontol 2001 reported that frailty affects 7% of community-dwelling adults over 65 and rises to over 30% in those over 80. Frail patients have higher susceptibility to volume depletion and lower lean body mass, which may amplify the blood pressure-lowering effects of dapagliflozin. Current evidence does not support a dose reduction in frail patients, but extra caution around diuretic co-prescribing is warranted.

Patients with Preserved Ejection Fraction Heart Failure

The DELIVER trial (N=6,263) tested dapagliflozin in HF with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). The primary composite of worsening HF or cardiovascular death was reduced by 18% (HR 0.82, 95% CI 0.73 to 0.92, P<0.001). Solomon et al., NEJM 2022 enrolled a mean age of 72 years, making this the most geriatric-representative of the major dapagliflozin outcome trials. The data support starting or continuing dapagliflozin in older adults with HFpEF, a population with previously few evidence-based pharmacologic options.

Patients with Both CKD and Heart Failure

The DAPA-CKD and DAPA-HF trials allowed co-enrollment criteria to overlap. A patient with both CKD (eGFR 30 to 44) and HFrEF may have two independent indications for dapagliflozin. The 2022 KDIGO Heart Failure in CKD guideline explicitly recommends SGLT2 inhibitors as first-line agents in patients with CKD and co-existing heart failure regardless of diabetes status, a recommendation that applies directly to many patients in the geriatric age category.